A retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer.
Frazier TG, Fox KR, Smith JS, Laronga C, McSwain A, Paul D, Schultz M, Stilwill J, Teal C, Weisberg T, Vacchino JF, Sing AP, Cherepanov D, Hsiao W, Chang E, Broder MS.
Frazier TG, et al. Among authors: cherepanov d.
Pharmaceuticals (Basel). 2015 Mar 17;8(1):107-22. doi: 10.3390/ph8010107.
Pharmaceuticals (Basel). 2015.
PMID: 25789420
Free PMC article.